ENGOT-ov43/MK-7339/KEYLYNK-001

Trial Description: 
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Lead Cooperative Group: 
Disease Site: 
Ovarian newly diagnosed
Trial Status: 
Recruiting
Contact person: